Developer docs
API playgroundTry for free, no card

Search company profiles

Limerston Capital

Full company profile

uuid00022el

Namestring
Limerston Capital
Legal namestring
Limerston Capital LLP
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Limerston Capital is a UK mid-market private equity firm founded in 2015 by James Paget, João Rosa, and Martim Avillez. The firm pursues control investments in UK lower mid-market companies with EBITDA between £5 million and £15 million, targeting sectors including Healthcare & Life Sciences, Business & Financial Services, TICC (Testing, Inspection, Certification & Compliance), Leisure, Niche Industrials, and Education. Its stated differentiator is an operationally focused model in which an in-house team of operating partners works alongside portfolio company management from first meeting through exit, combined with a buy-and-build approach to create category leaders. The firm holds 12 platforms and has completed 41 cumulative bolt-on acquisitions.

The firm manages approximately £525 million in assets under management across two blind-pool funds, with Limerston Capital Partners II reaching a £245 million final close in March 2024. Limited partners span US, Asian, and European institutional investors including corporate pension plans, university endowments, charitable foundations, family offices, and fund managers. Limerston is authorised and regulated by the UK Financial Conduct Authority and operates from offices in London. Origination is driven by direct outreach, intermediary relationships, and operating-partner networks rather than broad-based marketing.

Revenue is generated primarily through private equity fund management fees on committed capital plus performance-related carry realized on exits. The firm has completed multiple realizations from Fund I, including the sales of Arch Sciences to Element (>30% IRR), Prism Healthcare to Charme Capital Partners (34% IRR), Village Bakery to Groupe Menissez (>3.5x MoM and 50% IRR), and elementsuite to Zellis Group. Recent strategic activity includes geographic expansion into the US (Cormica/TPM Laboratories) and Germany (Cormica/Zwisler Laboratorium), platform creation in biorepository services (Astoriom carve-out from Source BioScience), and entry into cyber security via the Xypher platform built through CyberCrowd, DigitalXRAID, and Aristi.

Short descriptiontext

UK mid-market private equity firm Limerston Capital manages £525M AUM across two funds. Founded in 2015, it executes control buy-and-build investments in UK companies with EBITDA of £5M-£15M across healthcare, business services, TICC, and other sectors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity investments, buyout fund management, buy-and-build strategy, mid-market acquisitions, operational transformation
Industry3 codes
PRIMARYFSANABAD
Small-Cap / Micro-Buyout
SECONDARYFSANABAE
Industry-Specialist Buyout (Sector-Focused)
SECONDARYFSANACAD
Business Services (B2B) Growth Equity
NAICS code2 codes
  • All Other Financial Investment Activities52399
  • Other Financial Investment Activities5239
SIC code1 code
  • Investors, Nec6799
Product category
Private Equity Fund Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Private Equity Fund Management
TypeManaged Services
Description

Limerston Capital generates returns through equity investments in portfolio companies, creating value through operational improvements, bolt-on acquisitions, and strategic repositioning, then realizing returns through exits to strategic buyers or other investors.

limerstoncap.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Limerston Capital Partners I
Description

First fund vehicle of Limerston Capital focusing on UK mid-market investments

limerstoncap.com
+1 more record
Core offering1 text field

Limerston Capital is a UK lower mid-market private equity firm that makes control investments in companies with EBITDA between £5 million and £15 million. The firm deploys capital alongside in-house operational expertise and executes buy-and-build strategies to create category leaders across Healthcare & Life Sciences, Business & Financial Services, TICC, Leisure, Niche Industrials, and Education sectors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Village Bakery exit delivered >3.5x MoM (Money on Money) and 50% IRR
+4 more records
Product overview1 text field

Limerston Capital is a UK mid-market private equity investment firm, not a technology product company. The firm provides private equity investment services and does not offer a unified software product or platform. Its portfolio consists of investee companies across various sectors including healthcare, life sciences, business services, and cybersecurity. These portfolio companies operate independently and are not integrated under a common Limerston Capital product platform.

Product and service2 records
1Limerston Capital Partners I LP
CategoryPrivate Equity Fund
2Limerston Capital Partners II
CategoryPrivate Equity Fund
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Ropes & Gray LLP served as legal adviser for Limerston Capital Partners II.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
TypeDirect peer
Description

UK lower mid-market PE firm investing across sectors with focus on management buyouts, growth capital and buy-and-build. Directly comparable in target company size, sector breadth, and UK mid-market focus.

3Bowmark Capital
TypeDirect peer
Description

UK lower mid-market PE firm targeting UK businesses with EBITDA typically between £5-£25M, executing buy-and-build strategies in Business Services, Healthcare, and Technology. Closely aligned with Limerston's size, strategy and sector mix.

TypeDirect peer
Description

UK mid-market PE firm executing buyouts and growth investments across Business Services, Healthcare and Consumer. Comparable size bracket and buy-and-build approach to UK lower mid-market opportunities.

TypeDirect peer
Description

UK mid-market PE firm investing in growth businesses across Business Services, Financial Services, TICC and Healthcare sectors with similar EBITDA target band. Directly comparable investment approach and sector overlap.

TypeDirect peer
Description

UK lower mid-market PE firm focused on growth buyouts and buy-and-build strategies in Business Services, Healthcare and Education. Highly comparable in fund size, target profile, and operational engagement model.

TypeBroad incumbent
Description

European mid-market PE firm with significant UK exposure and broad sector mandate. Larger fund size but overlapping target markets in lower mid-market and similar buy-and-build execution.

TypeBroad incumbent
Description

Large European PE/venture investor with UK focus on technology and services. Broader portfolio and larger fund size, but comparable in UK mid-market deal flow and sector overlap in business services and software.

TypeDirect peer
Description

UK mid-market PE firm executing buyouts across diverse sectors with buy-and-build approach. Comparable in fund size, target EBITDA range and operationally-focused investment style.

TypeBroad incumbent
Description

UK and European mid-market PE firm with focus on technology, business services and consumer brands. Larger fund vehicles but comparable buy-and-build approach in UK and European markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries13 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A12 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Limerston Capital

Private Equity Fund Managementlimerstoncap.com

UK mid-market private equity firm Limerston Capital manages £525M AUM across two funds. Founded in 2015, it executes control buy-and-build investments in UK companies with EBITDA of £5M-£15M across healthcare, business services, TICC, and other sectors.

What Limerston Capital does

Limerston Capital is a UK mid-market private equity firm founded in 2015 by James Paget, João Rosa, and Martim Avillez. The firm pursues control investments in UK lower mid-market companies with EBITDA between £5 million and £15 million, targeting sectors including Healthcare & Life Sciences, Business & Financial Services, TICC (Testing, Inspection, Certification & Compliance), Leisure, Niche Industrials, and Education. Its stated differentiator is an operationally focused model in which an in-house team of operating partners works alongside portfolio company management from first meeting through exit, combined with a buy-and-build approach to create category leaders. The firm holds 12 platforms and has completed 41 cumulative bolt-on acquisitions.

The firm manages approximately £525 million in assets under management across two blind-pool funds, with Limerston Capital Partners II reaching a £245 million final close in March 2024. Limited partners span US, Asian, and European institutional investors including corporate pension plans, university endowments, charitable foundations, family offices, and fund managers. Limerston is authorised and regulated by the UK Financial Conduct Authority and operates from offices in London. Origination is driven by direct outreach, intermediary relationships, and operating-partner networks rather than broad-based marketing.

Revenue is generated primarily through private equity fund management fees on committed capital plus performance-related carry realized on exits. The firm has completed multiple realizations from Fund I, including the sales of Arch Sciences to Element (>30% IRR), Prism Healthcare to Charme Capital Partners (34% IRR), Village Bakery to Groupe Menissez (>3.5x MoM and 50% IRR), and elementsuite to Zellis Group. Recent strategic activity includes geographic expansion into the US (Cormica/TPM Laboratories) and Germany (Cormica/Zwisler Laboratorium), platform creation in biorepository services (Astoriom carve-out from Source BioScience), and entry into cyber security via the Xypher platform built through CyberCrowd, DigitalXRAID, and Aristi.

Limerston Capital firmographics

Firmographics
Name
Limerston Capital
Legal name
Limerston Capital LLP
Website
https://limerstoncap.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
UK mid-market private equity firm Limerston Capital manages £525M AUM across two funds. Founded in 2015, it executes control buy-and-build investments in UK companies with EBITDA of £5M-£15M across healthcare, business services, TICC, and other sectors.
Ownership category
akta.pro rank

Limerston Capital industry classification

Industry
Product category
Private Equity Fund Management
NAICS
All Other Financial Investment Activities (52399), Other Financial Investment Activities (5239)
SIC
Investors, Nec (6799)
akta.pro industry
PRIMARYFSANABAD
Small-Cap / Micro-Buyout
SECONDARYFSANABAE
Industry-Specialist Buyout (Sector-Focused)
SECONDARYFSANACAD
Business Services (B2B) Growth Equity

Keywords

  • Private equity investments
  • Buyout fund management
  • Buy-and-build strategy
  • Mid-market acquisitions
  • Operational transformation

Where Limerston Capital is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Limerston Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Private Equity Fund Management: Limerston Capital generates returns through equity investments in portfolio companies, creating value through operational improvements, bolt-on acquisitions, and strategic repositioning, then realizing returns through exits to strategic buyers or other investors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Limerston Capital product offering

Product offering

Core offering

Limerston Capital is a UK lower mid-market private equity firm that makes control investments in companies with EBITDA between £5 million and £15 million. The firm deploys capital alongside in-house operational expertise and executes buy-and-build strategies to create category leaders across Healthcare & Life Sciences, Business & Financial Services, TICC, Leisure, Niche Industrials, and Education sectors.

Product overview

Limerston Capital is a UK mid-market private equity investment firm, not a technology product company. The firm provides private equity investment services and does not offer a unified software product or platform. Its portfolio consists of investee companies across various sectors including healthcare, life sciences, business services, and cybersecurity. These portfolio companies operate independently and are not integrated under a common Limerston Capital product platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Limerston Capital Partners I: First fund vehicle of Limerston Capital focusing on UK mid-market investments
  • Limerston Capital Partners II

Products and services

  • Limerston Capital Partners I LP
  • Limerston Capital Partners II

Quantifiable outcome

  • Village Bakery exit delivered >3.5x MoM (Money on Money) and 50% IRR
  • +4 more outcomes

Companies that use Limerston Capital

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles2 records

Limerston Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Limerston Capital partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ropes & Gray LLPsupportingImplementation/ SI/ Consulting PartnerRopes & Gray LLP served as legal adviser for Limerston Capital Partners II.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Limerston Capital competitors and assessment

Company assessment

Others

Direct peers

  • LDC (Lloyds Development Capital): UK lower mid-market PE firm investing across sectors with focus on management buyouts, growth capital and buy-and-build. Directly comparable in target company size, sector breadth, and UK mid-market focus.
  • Bowmark Capital: UK lower mid-market PE firm targeting UK businesses with EBITDA typically between £5-£25M, executing buy-and-build strategies in Business Services, Healthcare, and Technology. Closely aligned with Limerston's size, strategy and sector mix.
  • Inflexion Private Equity: UK mid-market PE firm executing buyouts and growth investments across Business Services, Healthcare and Consumer. Comparable size bracket and buy-and-build approach to UK lower mid-market opportunities.
  • ECI Partners: UK mid-market PE firm investing in growth businesses across Business Services, Financial Services, TICC and Healthcare sectors with similar EBITDA target band. Directly comparable investment approach and sector overlap.
  • Lyceum Capital: UK lower mid-market PE firm focused on growth buyouts and buy-and-build strategies in Business Services, Healthcare and Education. Highly comparable in fund size, target profile, and operational engagement model.
  • Endless LLP: UK mid-market PE firm executing buyouts across diverse sectors with buy-and-build approach. Comparable in fund size, target EBITDA range and operationally-focused investment style.

Broad incumbents

  • Bridgepoint Group: European mid-market PE firm with significant UK exposure and broad sector mandate. Larger fund size but overlapping target markets in lower mid-market and similar buy-and-build execution.
  • Hg Capital: Large European PE/venture investor with UK focus on technology and services. Broader portfolio and larger fund size, but comparable in UK mid-market deal flow and sector overlap in business services and software.
  • Oakley Capital: UK and European mid-market PE firm with focus on technology, business services and consumer brands. Larger fund vehicles but comparable buy-and-build approach in UK and European markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Limerston Capital social profiles

Digital presence

Limerston Capital compliance and trust

Trust signal

Compliance9 records

Limerston Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Limerston Capital leadership team

Management profile

Number of profiles

Profiles21 records

Limerston Capital subsidiaries and ownership

Company hierarchy

Subsidiaries13 records

Limerston Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Limerston Capital M&A and investment

M&A and investment

M&A12 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Limerston Capital

What does Limerston Capital do?

Limerston Capital is a UK lower mid-market private equity firm that makes control investments in companies with EBITDA between £5 million and £15 million. The firm deploys capital alongside in-house operational expertise and executes buy-and-build strategies to create category leaders across Healthcare & Life Sciences, Business & Financial Services, TICC, Leisure, Niche Industrials, and Education sectors.

Is Limerston Capital a public or private company?

Limerston Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Limerston Capital founded?

Limerston Capital was founded in 2015. It employs 11 to 50 people.

Where is Limerston Capital based?

Limerston Capital is headquartered in London, United Kingdom, in the Europe region.

How does Limerston Capital make money?

One revenue line is on record: private Equity Fund Management.

Who are Limerston Capital's main competitors?

Graphite Capital is listed as an others. Direct peers are LDC (Lloyds Development Capital), Bowmark Capital, Inflexion Private Equity, ECI Partners, Lyceum Capital and Endless LLP. Broad incumbents are Bridgepoint Group, Hg Capital and Oakley Capital.

Does Limerston Capital have an API?

No public API is recorded for Limerston Capital.

What industry is Limerston Capital in?

Limerston Capital's product category is Private Equity Fund Management. Its primary akta.pro industry code is FSANABAD, Small-Cap / Micro-Buyout, with a secondary code of FSANABAE, Industry-Specialist Buyout (Sector-Focused). Its NAICS code is 52399 and its SIC code is 6799.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The UKIgnoring evolving cyber security threat is not an option for businessesXypher CEO Matthew Parker has warned businesses that ignoring the evolving cybersecurity landscape, particularly with the emergence of AI as a new threat vector, is not a viable option. The cybersecurity firm, backed by private equity firm Limerston Capital, recently opened a new office in Leeds as part of its growth strategy. Parker brings over 26 years of senior software industry experience to his role.MarketScreenerNatWest to sell HR consultancy unit Mentor in streamlining pushNatWest announced the sale of its HR consultancy subsidiary Mentor to private equity-backed Empowering People Group as part of its operational streamlining to focus on core banking and wealth management. Mentor, launched in 1997, has 220 employees who will all transfer to the buyer upon closing, expected in the third or early fourth quarter of 2026. Financial terms of the deal were not disclosed, and Empowering People Group is backed by London-based buyout firm Limerston Capital.InsidermediaLimerston Capital invests in CyberCrowd - HMT advisesLimerston Capital invested in CyberCrowd, a cybersecurity firm, in a deal advised by HMT. The investment will create a new platform business alongside assets from an earlier acquisition, adding digital forensic and e-discovery capabilities. The group plans to focus on core growth priorities, including further M&A.LimerstoncapLimerston Capital acquires CyberCrowd to create new cyber security platformLimerston Capital acquired CyberCrowd, a UK-based cyber security services firm, to build a new platform business. The combined group offers digital forensics, incident response, and 24/7 SOC services for public and private clients. The group plans to explore further expansion in the cyber security market.CybercrowdLimerston Capital acquires CyberCrowd to create new cyber security platform – CyberCrowdLimerston Capital acquired CyberCrowd, a UK cyber security services firm, to build a new platform combining digital forensics, SOC, and incident response. The combined group will offer end-to-end cyber resilience to public and private sector clients, with plans for further expansion.EIN PresswireConcept Life Sciences expands expertise with key appointments to Scientific Advisory Board and investments to strengthen integrated drug discovery capabilitiesConcept Life Sciences appointed Professor Luke O'Neill and Dr. Shane Liddelow to its Scientific Advisory Board, with Dr. Ian Waddell continuing on the board. The company invested a five-figure sum in GBP to enhance automated ADME systems and purchase a Supercritical Fluid Chromatography instrument. These moves follow its acquisition of Charnwood Discovery and aim to strengthen integrated drug discovery services.LimerstoncapLimerston Capital exits Village BakeryLimerston Capital has completed the exit of its investment in Village Bakery by selling it to Groupe Menissez, achieving a return in excess of 3.5x MoM and 50% IRR. The transaction follows significant growth for Village Bakery, including the opening of a new facility in Wrexham and a doubling of staff since Limerston's 2021 investment.Pulse 2.0Limerston Capital: Fund II Closed With £245 Million In CommitmentsLimerston Capital closed its second fund, Limerston Capital Partners II, with £245 million in commitments, up from its inaugural fund. The fund targets UK businesses with EBITDA of £5-15 million and has made three investments, including Largo Leisure, Concept Life Sciences, and Astoriom.InvestorsinhealthcareUK: Limerston Capital acquires Source BioScience’s Stability Storage businessLimerston Capital has completed the acquisition of the Stability Storage business from Source BioScience. Source BioScience is a provider of laboratory services in genomics and histopathology. The transaction highlights strategic moves within the UK mid-market private equity sector.MilbankMilbank Advises Limerston Capital on Its Acquisition of Stability Storage Business Unit (Renamed Astoriom) of Source BioScienceMilbank LLP advised Limerston Capital on its acquisition of the Stability Storage business unit, now renamed Astoriom, from Source BioScience. The transaction creates a standalone company focused on biorepository services, enabling expansion in high-value pharmaceutical and biologic markets across the US and Europe.